Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822258 | 0.88 | EPHX2 (0.55) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4817714 | 0.84 | MAPT (0.50) | EPHX2ALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4820586 | 0.82 | CTSK (0.50) | EPHX2SMN1; SMN2 | |
| SCHEMBL4823780 | 0.82 | CTSK (0.50) | EPHX2SMN1; SMN2 | |
| SCHEMBL4826932 | 0.74 | MTNR1A (0.43) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1420593 | 0.73 | POLB (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL24283531 | 0.73 | SMN1; SMN2 (0.58) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4819482 | 0.73 | SMN1; SMN2 (0.41) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27601529 | 0.72 | POLB (0.46) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4868745 | 0.72 | L3MBTL1 (0.61) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | EPHX2 4212/4885ALDH1A1 1616/4885NPC1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.